TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32482355
Drug: 0.3 μg.kg−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg.kg−1 remifentanil combined with propofol
Study: 32610864
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Study: 32610864
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Study: 32610864
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day oral iron supplementation
Study: 34105575
Drug: 3 whole
Normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 whole Gala apples (∼200 g)
Study: 35142833
Drug: Computer-Assisted Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Assisted Cognitive Behavior Therapy (CCBT)
Study: 33361317
Drug: Navy bean
Normalized name: navy bean
DrugBank: Kidney bean (DB10639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navy bean intervention (35 g bean powder/day)
Study: 34383381
Drug: MMC + cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMC + cytosine arabinoside (Ara‐C) therapy (30 mg/30 mL + 200 mg/10 mL) for 6 weeks
Study: 34383381
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) therapy (30 mg/40 mL) for 6 weeks
Study: 34383381
Drug: MMC + Ara‐C therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC + Ara‐C therapy
Study: 34383381
Drug: MMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC therapy
Study: 34383381
Drug: MMC and
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC and Ara‐C therapy
Study: 32114796
Drug: Twice-daily 30-second
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily 30-second ECGs during 14 days
Study: 32641226
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg twice daily
Study: 33113452
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)
Study: 32588803
Drug: Vi-polysaccharide (ViPS)
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-polysaccharide (ViPS) typhoid vaccine
Study: 32314015
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg vaginal dinoprostone
Study: 35771891
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside (20 mg.kg‐1 up to 1000 mg over 30 minutes)
Study: 34593344
Drug: Intervention involving
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention involving the use of the PADR-EC ADR score communicated to clinicians and discussed with participants, followed by medication management advice to general practitioners and community pharmacists.
Study: 33491087
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (HbA1c < 6.2%, blood pressure < 120/75 mm Hg, LDL-cholesterol < 80 mg/dL)
Study: 33491087
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (HbA1c < 6.9%, blood pressure < 130/80 mm Hg, LDL-cholesterol < 120 mg/dL)
Study: 33491087
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of pioglitazone at 1 year after randomization
Study: 32004772
Drug: Fluvastatin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (multiple oral doses: 20, 40 or 80 mg/day for 7 days)
Study: 32004772
Drug: Atorvastatin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (single oral dose: 20, 40 or 80 mg)
Study: 34032727
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg qd diltiazem sustained-release capsules)
Study: 34032727
Drug: Nicorandil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (5 mg tid nicorandil tablets)
Study: 34032727
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug treatments (aspirin, atorvastatin, betaloc ZOK, perindopril, and isosorbidemononitrate sustained-release tablets)
Study: 32854772
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg OD Rivaroxaban treatment for 11 to 17 days
Study: 35622608
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of the pretarsal segment of the upper eyelid
Study: 38356864
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use
Study: 32556710
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy in addition to standard urotherapy
Study: 33233717
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment for postpartum depression provided in healthcare centers
Study: 33233717
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment for postpartum depression
Study: 32303437
Drug: Anti-EGFR agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-EGFR agents exposure
Study: 33097365
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment with physiologic voice therapy plus vocal hygiene program (n = 17)
Study: 33988941
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and sacroiliac joints home‐based exercise program
Study: 33988941
Drug: Sacroiliac joints
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacroiliac joints manual therapy and home‐based lumbar exercise program
Study: 32278735
Drug: Chronic kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic kidney disease defined by an eGFR < 60 mL/min/1.73 m2
Study: 32278735
Drug: Nephrotoxic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrotoxic treatment
Study: 33551165
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d of YS powder
Study: 33551165
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of YS powder
Study: 33551165
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d of YS powder
Study: 33551165
Drug: 9 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g/d of YS powder
Study: 35306405
Drug: daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: daridorexant 50 mg
Study: 32696600
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step count during quarantine
Study: 32696600
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily step count before and during quarantine
Study: 35638548
Drug: Upfront ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront ABVD plus radiation therapy
Study: 35638548
Drug: Baseline TMTV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline TMTV ≥155 mL
Study: 33097977
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg orally 1 hour before ESP
Study: 33097977
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (single session immediately after ESP)
Study: 33097977
Drug: Placebo lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lactose tablets orally 1 hour before ESP
Study: 36285484
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation training during standard occupational therapy sessions for three weeks.
Study: 36285484
Drug: Standard occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard occupational therapy (control group).
Study: 33124670
Drug: Insulin independence
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin independence
Study: 32290122
Drug: GS mint
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS mint (4 mg of gymnemic acids)
Study: 32891709
Drug: n-acetylcysteine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-acetylcysteine 1.2 g
Study: 32891709
Drug: n-acetylcysteine 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-acetylcysteine 2.4 g
Study: 32588088
Drug: Complex model
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex model (combination of radiomic and clinical models)
Study: 32776099
Drug: Nomogram including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nomogram including age, race, tumor site, depth of tumor invasion, lymph node status, distant metastasis, tumor size, surgery, chemotherapy and radiotherapy.
Study: 32789505
Drug: Low-dose (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (2.5 μg/dose)
Study: 32789505
Drug: Medium-dose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose (5 μg/dose)
Study: 32789505
Drug: High-dose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (10 μg/dose)
Study: 32789505
Drug: Vaccine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (5 μg/dose) on days 0 and 14
Study: 32789505
Drug: Vaccine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (5 μg/dose) on days 0 and 21
Study: 32156534
Drug: Organic Zinc
Normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Zinc (Zn) 20 mg/kg DM
Study: 32156534
Drug: Organic Zinc
Normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Zinc (Zn) 40 mg/kg DM
Study: 32156534
Drug: Organic Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Copper (Cu) 12.5 mg/kg DM
Study: 32156534
Drug: Organic Zinc
Normalized name: ZINC OXIDE 25 g in 100 g TOPICAL LOTION [ORGANIC ZINCLEAR SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Zinc (Zn) 60 mg/kg DM
Study: 32156534
Drug: Organic Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Copper (Cu) 25 mg/kg DM
Study: 32156534
Drug: Organic Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic Copper (Cu) 37.5 mg/kg DM
Study: 32156534
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Zn 60 + Cu 37.5 mg/kg DM
Study: 35084071
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 35 or 70 mg + exposure therapy
Study: 35084071
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + exposure therapy
Study: 35084071
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) + exposure therapy
Study: 32011017
Drug: Environmental exposures
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental exposures (including socio-economic status, water source, sanitary facility, domestic animals, maternal characteristics, season, antibiotic use, and delivery mode)
Study: 35787135
Drug: GCSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF (300 μg subcutaneously administered two days after IUI)
Study: 35846327
Drug: Progesterone +
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone + Metformin
Study: 32060156
Drug: Standard SWMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SWMS care plus a targeted prescribing pathway for LIRA 3 mg
Study: 33412557
Drug: Nifurtimox 10–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifurtimox 10–20 mg/kg/day (aged <12 years) or 8–10 mg/kg/day (aged ≥12 years) for 60 days
Study: 35301982
Drug: Ureteroscopic stone
Normalized name: ditch stonecroft extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureteroscopic stone treatment
Study: 35930976
Drug: High-flow normobaric
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow normobaric oxygen (NBO) by Venturi mask (FiO2 50%, flow 15 L/min) for 6 hours
Study: 35930976
Drug: Routine low-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine low-flow oxygen supplementation by nasal cannula (flow 3 L/min) for 6 hours
Study: 32677170
Drug: Doublebase gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase gel (DBG)
Study: 32677170
Drug: Myribase gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myribase gel (MBG)
Study: 35219776
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice a day) with RDI >98%
Study: 35219776
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice a day) with RDI 90%-98%
Study: 35219776
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice a day) with RDI <90%
Study: 32642957
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) ketamine (30 and 50 mg)
Study: 33246021
Drug: Alpelisib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (300 mg/day) plus fulvestrant (500 mg every 28 days and once on day 15)
Study: 35750737
Drug: Amoxicillin 2
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 2 grams preoperatively
Study: 33002553
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg/day with Metformin 1000 mg/day
Study: 36309760
Drug: Enteral Nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral Nutrition (EN) starting on postoperative day (POD) 1 at 200-300 ml/day, increased to 400-600 ml/day on POD 2, depending on surgeon's decision from POD 3.
Study: 36309760
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups start oral feeding on POD 3.
Study: 34328151
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Salmon milt peptide (SMP) administered continuously or as a single dose for one week
Study: 36164011
Drug: Rusfertide (10-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rusfertide (10-120 mg weekly)
Study: 36164011
Drug: Rusfertide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rusfertide (40 mg SQ twice weekly)
Study: 33119898
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus azacitidine (AZA; 75 mg/m2; days 1-7)
Study: 33119898
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus decitabine (DEC; 20 mg/m2; days 1-5)
Study: 34389504
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy for peanut allergy
Study: 32578472
Drug: 7-day intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Study: 32578472
Drug: 14-day intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day intake of NZBC extract (600 mg containing 210 mg of anthocyanins)
Study: 33112049
Drug: Hazelnut oil
Normalized name: Hazelnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut oil containing 24.2 mg kg‐1 2‐MCPD and 54.5 mg kg‐1 3‐MCPD
Study: 33112049
Drug: Background excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background excretion before exposure
Study: 33546610
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) combined with sit-to-stand (STS) exercises for 12 weeks
Study: 616791867
Drug: TAS‐102 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS‐102 35 mg/m² orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28‐day cycle (n = 534)
Study: 616791867
Drug: TAS‐102 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS‐102 35 mg/m²
Study: 33925049
Drug: 50% whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% whole grain cereals with 12 g sugar (50-WG)
Study: 33925049
Drug: 0% whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% whole grain cereals with 24 g sugar (0-WG)
Study: 33788461
Drug: Heat-sensitive moxibustion
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-sensitive moxibustion combined with western medication
Study: 33788461
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medication (alendronate sodium tablet, calcium carbonate, vitamin D3 tablet)
Study: 34252203
Drug: 8 L
Normalized name: PEG-8 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 L of balanced hypotonic electrolyte supplement
Study: 34252203
Drug: 1 to
Normalized name: Cep-11981 tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 3 L of water
Study: 34252203
Drug: 8 L
Normalized name: PEG-8 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 L of balanced hypotonic electrolyte supplement with 42K
Study: 35213517
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/100 mg P4
Study: 35213517
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg E2/100 mg P4
Study: 33420480
Drug: OCPs (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCPs (0.15 mg levonorgestrel + 0.30 μg ethinyl estradiol)
Study: 33225772
Drug: Phototherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy plus UDCA (10 mg/kg/day)
Study: 32875451
Drug: Pomegranate peel
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate peel supplementation via water (0.3 g L‐1)
Study: 32875451
Drug: Pomegranate peel
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate peel supplementation via diet (1 g PP powder/kg diet)
Study: 32875451
Drug: Pomegranate peel
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate peel supplementation via diet (2 g PP powder/kg diet)
Study: 32875451
Drug: Hg +
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hg + Pomegranate peel supplementation via water (0.3 g L‐1)
Study: 32875451
Drug: Hg +
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hg + Pomegranate peel supplementation via diet (1 g PP powder/kg diet)
Study: 32875451
Drug: Hg +
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hg + Pomegranate peel supplementation via diet (2 g PP powder/kg diet)
Study: 32029429
Drug: Cervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical injection of 99m Tc at the 3 and 9 o'clock positions of the uterine cervix
Study: 32029429
Drug: Endometrial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial injection of 99m Tc into the fundal endometrium using a transcervical catheter
Study: 36149164
Drug: Conventional field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Study: 36149164
Drug: Extended field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Study: 33300853
Drug: Systemic rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic rehydration (oral fluid consumption)
Study: 32325164
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose water (D5W) and corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Study: 32325164
Drug: Corticosteroid (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Study: 32007991
Drug: Global Postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global Postural Reeducation (GPR) method, implemented for 72 treatment sessions, 3 times a week for 24 weeks
Study: 34243836
Drug: TYRX Absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYRX Absorbable Antibacterial Envelope adjunctive to standard of care
Study: 35815323
Drug: Intracervical injection
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical injection of combination liposomal bupivacaine and bupivacaine
Study: 33539955
Drug: Gastroretentive tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroretentive tablets containing cilnidipine
Study: 33539955
Drug: Reference tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablets
Study: 34483276
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg height-based dosing) administered 4 times per year for 1 year
Study: 33728657
Drug: Combined Oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oral Contraceptive Pill (COCP)
Study: 36265101
Drug: Triple metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple metronomic chemotherapy (TMC): oral methotrexate 9 mg/m2 once a week, celecoxib 200 mg twice daily, erlotinib 150 mg once daily